Drug Approval | December 20, 2025
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
The company shall process the change of name application with BSE Ltd. in due course
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Subscribe To Our Newsletter & Stay Updated
